Research Paper

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

Eriseld Krasniqi
Laura Pizzuti
Maria Rosaria Valerio
Elisabetta Capomolla
Claudio Botti
Giuseppe Sanguineti
Paolo Marchetti
Elisabetta Anselmi
Silverio Tomao
Antonio Giordano
Corrado Ficorella
Katia Cannita
Lorenzo Livio
Icro Meattini
Maria Mauri
Filippo Greco
Enzo Maria Veltri
Andrea Michelotti
Luca Moscetti
Francesco Giotta
Vito Lorusso
Ida Paris
Federica Tomao
Daniele Santini
Giuseppe Tonini
Alice Villa
Vittorio Gobbio
Teresa Gamucci
Gennaro Ciliberto
Isabella Sperduti
Marco Mazzotta
Maddalena Barba
Patrizia Vici

1. Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
2. Department of Surgical, Oncological and Oral Sciences, Medical Oncology Unit, University of Palermo, Italy.
3. Department of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
4. Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
5. Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
6. Medical Oncology Unit, Azienda Ospedaliera Universitaria Sant'Andrea, Rome, Italy.
7. Department of Radiological, Oncological and Anatomopathological Sciences, ‘Sapienza’ University of Rome, Policlinico Umberto I, Rome, Italy.
8. Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA.
9. Medical Oncology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy.
10. Medical Oncology, St. Salvatore Hospital, L’Aquila, Italy.
11. Radiation Oncology Unit and Department of Clinical and Experimental Biomedical Sciences “Mario Serio”, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
12. Division of Oncology, San Giovanni Addolorata Hospital, Rome, Italy.
13. Department of Pathology, Surgery and Oncology, “Mater Salutis” Hospital, ULS821, Verona, Italy.
14. Oncology Unit, S. Maria Goretti Hospital, Latina, Italy.
15. I/O Oncologia Medica L.S. Chiaro Hospital, Dipartimento di Oncologia, Dei Trapiantati e Delle Nuove Tecnologie, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
16. Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
17. Department of Medical Oncology, “Giovanni Paolo II” Institute, Bari, Italy.
18. Gynecology Oncology Unit, Catholic University of the Sacred Heart, Rome, Italy.
19. Department of Gynecology-Obstetrics and Urology, “Sapienza” University of Rome, Policlinico Umberto I, Rome, Italy.
20. Department of Oncology, University Campus Biomedico of Rome, Rome, Italy.
21. Department of Oncology, Policlinico Universitario “A. Gemelli”, Rome, Italy.
22. Medical Oncology, La Maddalena Nursing Home, University of Palermo, Palermo, Italy.
23. Medical Oncology Unit, Sandro Pertini Hospital, Rome, Italy.
24. Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
25. Bio-Statistics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.10.25; Accepted: 2020.12.18; Published: 2021.03.27

Abstract

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment.

Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres.

Results: Median age was 51 years, with 11.4% of these patients being metastatic at diagnosis. Median overall survival (OS) and progression free survival (PFS) from eribulin starting were 11.9 (95%CI: 8.4-15.5) and 3.5 months (95%CI: 1.7-5.3), respectively. We observed 8 (18.2%) partial responses and 10 (22.7%) patients had stable disease as best response. A longer PFS on previous first line treatment predicted a better OS (HR=0.87, 95%CI: 0.77-0.99, p= 0.038) and a longer PFS on eribulin treatment (HR=0.92, 95%CI: 0.85-0.98, p=0.018). Progression free survival to eribulin was also favorably influenced by prior adjuvant chemotherapy (HR=0.44, 95%CI: 0.22-0.88, p=0.02). Eribulin was generally well tolerated, with grade 3-4 adverse events being recorded in 15.9% of patients.
Conclusions: The outcomes described for our cohort are consistent with those reported in the pivotal Study301 and subsequent observational studies. Further data from adequately-sized, ad hoc trials on eribulin use in second line for mTNBC are warranted to confirm our findings.

Key words: eribulin mesylate, triple negative metastatic breast cancer, efficacy outcomes, toxicity outcomes, chemotherapy

Introduction

Approximately 15\% of breast cancers are classified as triple-negative (TNBC), a subtype associated with aggressive clinical behavior and poor prognosis. Metastases in TNBC are described in about one-third of patients, with either recurrent or de novo metastatic disease [1].

Chemotherapy has long been considered the only active treatment for metastatic TNBC [2]. This latter scenario has recently changed with the advent of polyadenosine diphosphate-ribosepolymerase inhibitors (PARPis) for patients harboring BRCA mutations [3]. In addition, the contrasting evidence on the combination of chemotherapy and atezolizumab in patients with PD-L1 positive tumors intensely animates the scientific debate, due to the recently presented results from the IMpassion 130 and 131 trial [4,5].

Eribulin mesylate is a synthetic halichondrin B analog that inhibits the microtubule growth phase [6]. Among its non-mitotic mechanisms of action, it is worth mentioning its anti-angiogenetic effects and its ability to reverse epithelial-mesenchymal transition process [7,8]. Moreover, it was recently suggested an association between eribulin treatment and an increase in tumor-infiltrating lymphocytes (TILs), a relevant predictive and prognostic marker in triple negative (TN) disease [9]. Eribulin is approved for treatment of patients with advanced breast cancer who are refractory to other treatments. This is based on the results from the EMBRACE trial, wherein eribulin was compared to treatment of physician choice, and from the Study 301, which evaluated eribulin in comparison with capecitabine [10,11]. In specific regard to eribulin activity in TNBC, a pooled analysis including patients of the EMBRACE and 301 trials showed a survival benefit for patients receiving eribulin versus control or capecitabine [12]. However, only the 301 Study enrolled TNBC patients receiving eribulin in second-line [13].

Herein we present our work aimed at investigating second-line eribulin efficacy in mTNBC in a historical cohort of patients treated at 14 Italian cancer centres.

Methods

The TETRIS trial is a multicenter retrospective study which was designed to assess the efficacy of eribulin as second line of treatment in patients affected by mTNBC. The study was conducted in full accordance with the guidelines for Good Clinical Practice and the Declaration of Helsinki, and was approved by the institutional ethics committees of each center. Overall, 14 cancer centers adhered to our study. Written informed consent was obtained from all patients who remained alive at the time of trial approval. Patients were deemed suitable for inclusion in the TETRIS trial if diagnosed with mTNBC, and having received at least one cycle of eribulin (1.23 mg/m²) following failure of a first line chemotherapy. Eribulin had to be delivered between January 2013 and September 2019, since a minimum 12-month follow up was required. In addition, data availability was required concerning key patient- and disease clinical-pathological variables, along with treatment outcomes. Eribulin treatment was delivered until disease progression, unacceptable toxicity or patient refusal, and efficacy was evaluated according to Response Evaluation Criteria in Solid Tumors (v. 1.1). Adverse events were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (v.4.0).

The primary objectives of the study were progression free survival (PFS), and overall survival (OS). Secondary endpoints included objective response and safety outcomes. Explorative analyses for potential clinical-pathological predictors of efficacy were also performed.

Descriptive statistics were used to characterize the study sample. Performance status was assessed according to the Eastern Cooperative Oncology Group (ECOG PS) prior to and following eribulin treatment and compared by Wilcoxon test. The Kaplan-Meier method and log-rank test were used to estimate survival and compare the inherent data across subgroups defined upon clinically and molecularly relevant variables. Univariate and multivariate Cox proportional hazards regression models were developed/built to evaluate associations of clinical-pathologic features with PFS and OS. Multivariate analysis was carried out including only variables testing significant in univariate analysis. The SPSS software (SPSS version 21.0, SPSS Inc., Chicago, IL) was used for all statistical evaluations. The significance levels for all performed tests was set at p<0.05.
Table 1. Baseline characteristics of the TETRIS participants (N=44)

| Patients' Characteristics                              | N (%) |
|--------------------------------------------------------|-------|
| Age in years, median (range)                           | 51 (35-81) |
| Menopausal status at diagnosis                         |       |
| Premenopausal                                          | 17 (38.6) |
| Postmenopausal                                         | 27 (61.4) |
| Surgery on primary tumor                               |       |
| Yes                                                    | 23 (52.3) |
| No                                                     | 21 (47.7) |
| Histotype                                              |       |
| Ductal carcinoma                                       | 42 (95.5) |
| Lobular carcinoma                                      | 1 (2.3) |
| Other                                                  | 1 (2.3) |
| Triple-negative cancer at diagnosis                    |       |
| Yes                                                    | 40 (90.9) |
| No                                                     | 4 (9.1) |
| Tumor grade                                            |       |
| 2                                                      | 2 (4.5) |
| 3                                                      | 40 (90.9) |
| Missing                                                | 1 (2.3) |
| BRCA 1/2 mutation                                      |       |
| Yes                                                    | 1 (2.3) |
| No                                                     | 26 (59.1) |
| Unknown                                                | 17 (38.6) |
| Neoadjuvant chemotherapy                               |       |
| Yes                                                    | 10 (22.7) |
| No                                                     | 2 (4.5) |
| Neoadjuvant Carboplatin                                |       |
| Adjuvant chemotherapy                                  |       |
| Yes                                                    | 25 (56.8) |
| No                                                     | 3 (6.8) |
| Adjuvant Capecitabine                                  |       |
| Metastasis at diagnosis                                |       |
| Yes                                                    | 5 (11.4) |
| No                                                     | 39 (88.6) |
| Number of metastatic sites                             |       |
| 1                                                      | 13 (29.5) |
| 2                                                      | 20 (45.5) |
| >2                                                     | 11 (25.0) |
| Pattern of metastatic involvement                      |       |
| Visceral                                               | 22 (50.0) |
| Bone-only                                              | 2 (4.5) |
| Other                                                  | 20 (45.5) |
| First-line therapy                                     |       |
| Paclitaxel                                             | 3 (6.8) |
| Paclitaxel/Bevacizumab                                 | 14 (31.8) |
| Anthracyclines                                         | 2 (4.5) |
| Capecitabine                                           | 3 (6.8) |
| Platinum Salts                                         | 11 (25) |
| Other                                                  | 11 (25) |
| Pretreatment (neo-adjuvant plus first-line)            |       |
| Taxanes                                                | 38 (86.4) |
| Anthracyclines                                         | 27 (61.4) |
| Carboplatin                                            | 14 (31.8) |
| Capecitabine                                           | 6 (13.6) |
| Two agents                                             | 19 (43.2) |
| Three agents                                           | 12 (27.3) |
| ECOG PS at Eribulin start                              |       |
| 0                                                      | 17 (38.6) |
| 1                                                      | 24 (54.5) |
| 2                                                      | 2 (4.5) |
| Unknown                                                | 1 (2.3) |
| Third line treatment                                   |       |
| None                                                   | 18 (40.9) |
| Nab-paclitaxel                                         | 11 (25) |
| Gemcitabine + Vinorelbine                              | 3 (6.8) |
| Carboplatin + Gemcitabine                              | 3 (6.8) |
| Gemcitabine                                            | 1 (2.3) |
| Capecitabine                                           | 1 (2.3) |
| Other                                                  | 3 (6.8) |
| Fourth line treatment                                  |       |
| Platinum (Cis/Carbo)                                   | 2 (4.5) |
| Capecitabine                                           | 2 (4.5) |
| Anthracyclines                                         | 1 (2.3) |
| Other                                                  | 1 (2.3) |

Results

Forty-four patients met the study inclusion criteria. Main patient and tumor characteristics are shown in Table 1. Median PFS to the previous first line treatment was 7.0 months (range: 1.0-21.0), as calculated by the Kaplan Meier product limit (Suppl Table S1). The main clinical outcomes of eribulin treatment are listed in Suppl Table S2. Median PFS on second line eribulin was 3.5 months (range: 1.7-5.3), with a one-year-PFS rate of 16.7%. Median OS was 11.9 months (range: 8.4-15.5), with OS rates at 1-year and 2-years of 43.0% and 12.7%, respectively (Figure 1A and 1B). Second line eribulin did not yield any complete response (CR). However, 18.2% of partial responses (PR) and 22.7% of stable diseases (SD) were recorded.

The comparison of survival curves showed that having received a previous adjuvant treatment predicted a better PFS on second line eribulin with respect to not having received it (p=0.02, log-rank test) (Fig. 2). Also, PFS on first line treatment impacted PFS to second line eribulin. As shown in Suppl Figure 1, the survival curve for PFS on eribulin was more favorable for those patients who had experienced a PFS longer than 10 months on the previous line of treatment, with PFS rates on eribulin at 12 months of 43.0% vs. 9.8% (p=0.03, log-rank test). Interestingly, difference in ECOG PS at eribulin starting, namely, 0 compared to 1-2, did not influence survival (p=0.33, log-rank test). Univariate analysis (Suppl Table S3) confirmed that only adjuvant chemotherapy and first line PFS had a significant effect on eribulin PFS. Adjuvant treatment and PFS on first line maintained a significant effect on eribulin PFS in multivariate analysis. Likewise, PFS to first line treatment was positively related to a longer PFS on eribulin treatment, both when it was considered as a continuous variable or as a categorical variable with a 10 months cut-off value (Suppl Table S4).

Survival curves for OS only differed when stratifying patients according to PFS duration on first line and ECOG PS at eribulin start (Suppl Fig. 1B and 2). In more detail, patients whose PFS on first line > 6 months showed a better survival with respect to those whose PFS was ≤ 6 months, with 12-month OS rates being 58.7% vs. 26.8%, and 24-month OS rates being 14.0% vs. 8.9% (p=0.02, log-rank test), respectively. Similarly, patients with an ECOG PS at eribulin start of 0 had a better OS compared to those with ECOG PS ≥ 1, with respective OS rates of 63.6% vs. 26.7% at 12 months, and 27.3% vs. 0.0% at 24 months (p=0.003, log-rank test). In the univariate model (Suppl Table S5), the variables associated with a lower risk of death from eribulin start were the following: age, longer PFS on first line, PFS on first line > 6 months, and a better
ECOG PS at eribulin start. However, in multivariate analysis, only a longer PFS on first line remained as an independent predictor of better OS from eribulin start. Values on pre- and post eribulin ECOG PS were available for 41 patients. Its variation following eribulin treatment (Table 2) resulted statistically significant by using Wilcoxon test (p = 0.0001).

**Table 2. ECOG PS at eribulin start vs eribulin end. The TETRIS study (N:44)**

| ECOG PS at eribulin start | ECOG PS at eribulin end | Total |
|---------------------------|-------------------------|-------|
|                           | 0                       | 1     | 2     | 3     | 4     |
| ECOG PS 0                 | 6                       | 8     | 2     | 16    |
| ECOG PS 1                 | 10                      | 9     | 4     | 23    |
| ECOG PS 2                 | 1                       | 1     | 1     | 2     |
| Total                     | 6                       | 18    | 12    | 1     | 41    |

*Wilcoxon test: p=0.0001; ECOG PS: Eastern cooperative oncology group performance status.

**Table 3. Toxicity profile of the TETRIS study participants (N:44)**

|                        | All grades, N (%) | Grade 3, N (%) | Grade 4, N (%) |
|------------------------|-------------------|----------------|----------------|
| **Hematological**      |                   |                |                |
| Neutropenia            | 20 (45.5)         | 2 (4.5)        | 0              |
| Anemia                 | 18 (40.9)         | 1 (2.3)        | 0              |
| Thrombocytopenia       | 6 (13.6)          | 1 (2.3)        | 1 (2.3)        |
| **Non-hematological**  |                   |                |                |
| Fatigue                | 34 (77.3)         | 3 (6.8)        | 0              |
| Peripheral neuropathy  | 22 (50)           | 1 (2.3)        | 0              |
| Nausea/vomiting        | 20 (45.5)         | 0              | 0              |
| Diarrhea               | 5 (11.4)          | 0              | 0              |
| AST/ALT alterations    | 9 (20.4)          | 0              | 0              |

Eribulin administration was generally safe, and no toxic deaths occurred. Two patients (4.5%) discontinued treatment for gastrointestinal toxicity and neurotoxicity, respectively. The most frequent toxicities were fatigue (all grades, 33 patients, 77.3%) and peripheral neuropathy (all grades, 22; 50.0%) (Table 3). Grade 3/4 adverse events (AEs) were recorded in 7 patients (15.9%) and were mostly related to fatigue (3 patients, 6.8%) and neutropenia (2 patients, 4.5%).

In the whole cohort, 26 patients (59.1%) received a third line of treatment, which was more often represented by nab-paclitaxel or a gemcitabine-based regimen (Table 1).
Discussion

The present study mainly reports on the efficacy of eribulin administered as second-line therapy in mTNBC patients. Overall, eribulin treatment in our cohort was safe, with manageable toxicities. To our knowledge, evidence from literature concerning eribulin use in mTNBC as second-line treatment is lacking, with the majority of data being from retrospective studies [14-19]. In the pooled analysis of the EMBRACE trial and Study 301, the PFS on eribulin from TNBC patients was 2.8 months, but most of these patients had received more than 1 previous chemotherapy line [12]. Overall, our findings are consistent with results from randomized clinical trials (RCTs), thus confirming the activity of eribulin in the mTNBC subset even in a non-selected patient population.

This study has some limitations. In first place, the topic of interest was addressed using a retrospective design. Heterogeneity in the study population characteristics may represent a further focus of discussion. Further critiques may be fueled by the study sample size, which appears somewhat limited. This may be at least partly explained by the relatively low representation of TNBC among the molecularly defined breast cancer subtypes.

Our study also has some relevant strengths. The topic of choice is extremely timely and of vivid interest to a cancer research agenda. Indeed, TNBC patients represent the breast cancer subgroup with the highest need for innovative treatment options, as witnessed by the recent efforts of the scientific community aimed at broadening the available therapeutic armamentarium. The critical interpretation of the data herein presented, notwithstanding the limitations stemming from the retrospective approach, adds a block of evidence to the pivotal eribulin RCTs and other prior observational studies. In fact, to the best of our knowledge, in none of the prior studies of eribulin in mTNBC, independently on the study design, the authors have specifically focused on the exclusive use of this agent in second line.

In conclusion, our study confirms the role of eribulin as an efficacious and safe option of treatment in the landscape of mTNBC, and an early inclusion in the continuum of treatment strategies could increase the inherent clinical benefits.

Supplementary Material
Supplementary figures and tables. http://www.medsci.org/v18p2245s1.pdf

Acknowledgements
We thank Dr. Alessandro Zennaro and Ana Maria Edlisca for administrative assistance and technical support.

Availability of data and materials
The datasets used during the current study are available from the corresponding authors on reasonable request.

Authors’ contributions
Study conception and critical revision: EK, PV, LP, MM, MB. Manuscript drafting, study conduct and analysis planning: LP, EK, EC, MM, MB and PV. Data collection: EA, KC, LL, FG, EMV, AM, LM, FG, IP, DS, AV. Critically revised the manuscript for important intellectual content: MRV, CB, GS, PM, ST, AG, CF, LL, IM, FG, EMV, AM, LM, FG, VL, FT, DS, GT, AV, VG, IS, GC, MM and MB declare no conflict of interests. LP received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees from Roche, Pfizer, Novartis, Gentili. PM has/had a consultant/advisory role for BMS, Roche Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, and Incyte. AM received travel grants from Eisai, Celgene, Novartis; personal fees, advisory boards from Eisai, Novartis, Astra Zeneca, Teva, Pfizer, Celgene. LM received personal fees/advisory board from Roche, Novartis, Eisai, Pfizer. IP received personal fees/advisory boards from Roche, Pfizer, Novartis, Italfarmaco, Gentili, Pierre Fabre. TG received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili, Lilly. PV received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili. All authors read and approved the final version of this manuscript and are responsible for all the aspects of the work.

Competing Interests
EK, MRV, EC, CB, GS, EA, ST, AG, CF, KC, LL, IM, FG, EMV, FG, VL, MMau, FT, DS, GT, AV, VG, IS, GC, MM and MB declare no conflict of interests. LP received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees from Roche, Pfizer, Novartis, Gentili. PM has/had a consultant/advisory role for BMS, Roche Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, and Incyte. AM received travel grants from Eisai, Celgene, Novartis; personal fees, advisory boards from Eisai, Novartis, Astra Zeneca, Teva, Pfizer, Celgene. LM received personal fees/advisory board from Roche, Novartis, Eisai, Pfizer. IP received personal fees/advisory boards from Roche, Pfizer, Novartis, Italfarmaco, Gentili, Pierre Fabre. TG received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili, Lilly. PV received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili.

References
1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34. doi: 10.1158/1078-0432.CCR-06-3045.
2. Cardoso F, Senkus E, Costa A, Papadopoulou E, Aapro M, Andre F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192.
3. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450.
4. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, et al. Atezolizumab and Nab-Paclitaxel in...
Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615.

5. Miles DW, et al: Primary results from IMpassion131, a double-blind placebo-controlled randomized phase III trial of first-line paclitaxel atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. ESMO Virtual Congress 2020. Abstract LBA15. Presented September 19, 2020.

6. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010 Feb 16;49(6):1331-7. doi: 10.1021/bi901810u.

7. Agoulnik SI, Kawano S, Taylor N, Oestreich J, Matsui J, Chow J, Oda Y, Funahashi Y. Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro. Vasc Cell. 2014 Mar 1;6(1):3. doi: 10.1186/2045-824X-6-3.

8. Yoshiida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, et al. Eribulin mesylate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014 Mar 18;110(6):1497-505. doi: 10.1038/bjc.2014.80.

9. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010.

10. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollert P, Manikas A, Diéras V, Deolzier T, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60706-6.

11. Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Oda Y, He Y, Dutsch CE, Cortes J. Eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892.

12. Twelves C, Cortes J, Vahdat L, Olivo M, Ye Y, Kaufman PA, Awada A. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014 Dec;148(3):553-61. doi: 10.1007/s10549-014-3144-y.

13. Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27(8):1525-1531. doi:10.1093/annonc/mdw203.

14. Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, Di Lauro L, Fusi A, Tonini G, Sini V, et al. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J Cancer. 2014;5(5):520-7. doi: 10.7150/jca.8748.

15. Garrone O, Montemurro F, Saggia C, La Verde N, Vandone AM, Airoldi M, De Conciliis E, Donadio M, Lucio F, Polimeni MA, et al. Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life. Springerplus. 2016;5:59. doi: 10.1186/s40064-016-1705-x.

16. Barni S, Livraghi L, Morritt M, Vici P, Michelotti A, Cinieri S, Fontanella C, Porcu L, Del Mastro L, Puglisi F. Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study. Future Oncol. 2019 Jan;15(1):33-44. doi:10.2217/fon-2018-0324.

17. Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amadio A, Massimiani G, Pelle F, Kayal R, Vizza E, et al. Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. J Cancer. 2019; 10(24): 5903 –5914.doi: 10.7150/jca.35109.